Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).

Participants needed: 48
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sawa Ito, MDUpdated: Aug 18, 2026Locations: 1
Eligibility criteria

Age 50-70 years old or [+10]

Poor performance status with Karnofsky Score <70% [+26]

Read more
Status: Recruiting

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort. The study will further contribute to this effort through the collection of leukemia cells pre- and post-in vivo IFN-γ therapy. As in the previously conducted phase 1 trial, this trial will assess whether leukemia blasts are responsive to IFN-γ in vitro and in vivo. Single-cell RNA sequencing (scRNAseq) will be performed to evaluate transcriptomic changes induced by IFN-γ in leukemia cell subsets, including those with stem cell characteristics.

Participants needed: 57
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sawa Ito, MDUpdated: Aug 11, 2026Locations: 3
Eligibility criteria

Age ≥ 18 years [+14]

Primary engraftment failure after alloSCT [+15]

Read more